Matches in Nanopublications for { ?s ?p "There was no difference in the magnitude of serum RBP4 elevation between the obese and obese-diabetic groups, suggesting that obesity and insulin resistance, but not hyperglycaemia, are associated with elevated serum RBP4 in humans. Rosiglitazone reverses RBP4 elevation The anti-diabetic agent rosiglitazone is a peroxisome proliferator activated receptor-gamma (PPARg) agonist that improves insulin sensitivity17. Treatment of adipose-Glut4-/- mice with rosiglitazone for three weeks completely reversed their insulin resistance and glucose intolerance18." ?g. }
Showing items 1 to 4 of
4
with 100 items per page.
- _3 value "There was no difference in the magnitude of serum RBP4 elevation between the obese and obese-diabetic groups, suggesting that obesity and insulin resistance, but not hyperglycaemia, are associated with elevated serum RBP4 in humans. Rosiglitazone reverses RBP4 elevation The anti-diabetic agent rosiglitazone is a peroxisome proliferator activated receptor-gamma (PPARg) agonist that improves insulin sensitivity17. Treatment of adipose-Glut4-/- mice with rosiglitazone for three weeks completely reversed their insulin resistance and glucose intolerance18." provenance.
- _3 value "There was no difference in the magnitude of serum RBP4 elevation between the obese and obese-diabetic groups, suggesting that obesity and insulin resistance, but not hyperglycaemia, are associated with elevated serum RBP4 in humans. Rosiglitazone reverses RBP4 elevation The anti-diabetic agent rosiglitazone is a peroxisome proliferator activated receptor-gamma (PPARg) agonist that improves insulin sensitivity17. Treatment of adipose-Glut4-/- mice with rosiglitazone for three weeks completely reversed their insulin resistance and glucose intolerance18." provenance.
- _3 value "There was no difference in the magnitude of serum RBP4 elevation between the obese and obese-diabetic groups, suggesting that obesity and insulin resistance, but not hyperglycaemia, are associated with elevated serum RBP4 in humans. Rosiglitazone reverses RBP4 elevation The anti-diabetic agent rosiglitazone is a peroxisome proliferator activated receptor-gamma (PPARg) agonist that improves insulin sensitivity17. Treatment of adipose-Glut4-/- mice with rosiglitazone for three weeks completely reversed their insulin resistance and glucose intolerance18." provenance.
- _3 value "There was no difference in the magnitude of serum RBP4 elevation between the obese and obese-diabetic groups, suggesting that obesity and insulin resistance, but not hyperglycaemia, are associated with elevated serum RBP4 in humans. Rosiglitazone reverses RBP4 elevation The anti-diabetic agent rosiglitazone is a peroxisome proliferator activated receptor-gamma (PPARg) agonist that improves insulin sensitivity17. Treatment of adipose-Glut4-/- mice with rosiglitazone for three weeks completely reversed their insulin resistance and glucose intolerance18." provenance.